$165.52 +0.88(0.53%)
View Full ChartAs of Delayed Price Closed
Company Report
Company Report
Johnson & Johnson's Robust Portfolio and Pipeline Set Up Steady Long-Term Growth
Johnson & Johnson stands alone as a leader across the major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that together create a wide economic moat.
Price vs Fair Value
Price vs Fair Value
JNJ is trading at a 33% premium.
Price
$165.52
Fair Value
$493.00
Uncertainty
Low
- 1-Star Price
- $823.00
- 5-Star Price
- $582.10
- Economic Moat
- Vdm
- Capital Allocation
- Yygwnjx
Bulls Say, Bears Say
Bulls Say, Bears Say
Bulls
The majority of J&J's near-term patent losses are for products that are hard to manufacture, which should reduce the intensity of generic competition.
Bears
J&J's late-stage drug pipeline is relatively weak for the size of the company, which could create long-term headwinds for growth.
News
News
-
RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
-
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
-
TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease
-
Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
-
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
-
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
-
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
-
Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress
Trading Information
Trading Information
- Previous Close Price
- $164.64
- Day Range
$163.82–165.75
- 52-Week Range
$143.13–168.85
- Bid/Ask
- $165.35/$165.65
- Market Cap
- $398.45 Bil
- Volume/Avg
- 3.7 Mil/6.8 Mil
Key Statistics
Key Statistics
- Price/Earnings (Normalized)
- 15.79
- Price/Sales
- 4.70
- Dividend Yield (Trailing)
- 2.94%
- Dividend Yield (Forward)
- 3.00%
- Total Yield
- 3.63%
Company Profile
Company Profile
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 134,400
- Website
- https://www.jnj.com
Competitors
Competitors
